image
Healthcare - Biotechnology - NASDAQ - IT
$ 3.8096
-2.32 %
$ 69.7 M
Market Cap
-7.47
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GNTA stock under the worst case scenario is HIDDEN Compared to the current market price of 3.81 USD, Genenta Science S.p.A. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GNTA stock under the base case scenario is HIDDEN Compared to the current market price of 3.81 USD, Genenta Science S.p.A. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one GNTA stock under the best case scenario is HIDDEN Compared to the current market price of 3.81 USD, Genenta Science S.p.A. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
0 REVENUE
0.00%
-11.7 M OPERATING INCOME
-6.24%
-11.6 M NET INCOME
-37.36%
-11.2 M OPERATING CASH FLOW
-51.05%
-14.9 M INVESTING CASH FLOW
-54915.39%
531 FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-4.52 M OPERATING INCOME
8.40%
-4.04 K NET INCOME
17.35%
-2.06 K OPERATING CASH FLOW
43.22%
4.3 K INVESTING CASH FLOW
187.91%
271 FINANCING CASH FLOW
50818.23%
Balance Sheet Genenta Science S.p.A.
image
Current Assets 21.3 M
Cash & Short-Term Investments 18.8 M
Receivables 0
Other Current Assets 2.48 M
Non-Current Assets 1.09 M
Long-Term Investments 0
PP&E 57 K
Other Non-Current Assets 1.03 M
Current Liabilities 1.74 M
Accounts Payable 295 K
Short-Term Debt 0
Other Current Liabilities 1.44 M
Non-Current Liabilities 179 K
Long-Term Debt 0
Other Non-Current Liabilities 179 K
EFFICIENCY
Earnings Waterfall Genenta Science S.p.A.
image
Revenue 0
Cost Of Revenue 41.6 K
Gross Profit -41.6 K
Operating Expenses 11.7 M
Operating Income -11.7 M
Other Expenses -87.5 K
Net Income -11.6 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-57.00% ROE
-57.00%
-52.11% ROA
-52.11%
-56.92% ROIC
-56.92%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Genenta Science S.p.A.
image
Net Income -11.6 M
Depreciation & Amortization 42.5 K
Capital Expenditures -13.8 K
Stock-Based Compensation 740 K
Change in Working Capital -418 K
Others 386 K
Free Cash Flow -11.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Genenta Science S.p.A.
image
GNTA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Genenta Science S.p.A.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
18 years ago
Nov 15, 2006
Bought 18.8 K USD
Sanders Walter Lloyd
VP, Sales & Marketing
+ 25000
0.75 USD
18 years ago
Jun 23, 2006
Bought 91.3 USD
Sanders Walter Lloyd
VP, Sales & Marketing
+ 56
1.63 USD
18 years ago
Jun 15, 2006
Bought 388 USD
Sanders Walter Lloyd
VP, Sales & Marketing
+ 255
1.52 USD
18 years ago
Jun 15, 2006
Bought 486 USD
Sanders Walter Lloyd
VP, Sales & Marketing
+ 322
1.51 USD
18 years ago
May 12, 2006
Bought 21.9 K USD
Driscoll Martin J
Director
+ 15000
1.46 USD
20 years ago
May 05, 2004
Sell 2.54 M USD
ROSENWALD LINDSAY A MD
10 percent owner
- 513400
4.95 USD
20 years ago
May 03, 2004
Sell 7.58 M USD
ROSENWALD LINDSAY A MD
10 percent owner
- 1501900
5.05 USD
20 years ago
May 04, 2004
Sell 17 M USD
ROSENWALD LINDSAY A MD
10 percent owner
- 3446300
4.92 USD
20 years ago
May 04, 2004
Sell 12.7 M USD
ROSENWALD LINDSAY A MD
10 percent owner
- 2589800
4.92 USD
20 years ago
May 03, 2004
Sell 5.7 M USD
ROSENWALD LINDSAY A MD
10 percent owner
- 1128700
5.05 USD
20 years ago
May 05, 2004
Sell 1.91 M USD
ROSENWALD LINDSAY A MD
10 percent owner
- 385800
4.95 USD
20 years ago
May 03, 2004
Sell 603 K USD
ROSENWALD LINDSAY A MD
10 percent owner
- 119400
5.05 USD
20 years ago
May 04, 2004
Sell 1.35 M USD
ROSENWALD LINDSAY A MD
10 percent owner
- 273900
4.92 USD
20 years ago
May 05, 2004
Sell 202 K USD
ROSENWALD LINDSAY A MD
10 percent owner
- 40800
4.95 USD
20 years ago
Mar 23, 2004
Bought 47.1 K USD
ROSENWALD LINDSAY A MD
10 percent owner
+ 5000
9.42 USD
20 years ago
Mar 16, 2004
Bought 51.4 K USD
ROSENWALD LINDSAY A MD
10 percent owner
+ 5000
10.29 USD
21 years ago
Oct 20, 2003
Bought 50.4 K USD
ROSENWALD LINDSAY A MD
10 percent owner
+ 5000
10.07 USD
21 years ago
Sep 10, 2003
Bought 78.4 K USD
ROSENWALD LINDSAY A MD
10 percent owner
+ 5000
15.68 USD
7. News
TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE Over 230 Italian and U.S. executives, Italian government leaders, and investors attended the eighth edition of "Italy On the Move" Seven life sciences executives provided business insights during "Navigating Transatlantic Partnerships in Life Sciences" panel discussion and five Italian startups pitched their unique breakthroughs and investment opportunities Director General for the Promotion of Italy Mauro Battocchi discussed private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector 1 SAN FRANCISCO , Jan. 28, 2025 /PRNewswire/ -- The Italian Trade Agency (ITA) collaborated with the Ministry of Foreign Affairs and International Cooperation to host the eighth edition of "Italy on the Move," a side event during the 43rd annual J.P. Morgan Healthcare Conference 2025 at INNOVIT - The Italian Innovation and Culture Hub. prnewswire.com - 1 month ago
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master Services Agreement. This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta's cell therapy product, ensuring compliance with cGMP standards. globenewswire.com - 1 month ago
ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector 1 SAN FRANCISCO , Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. prnewswire.com - 1 month ago
Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” Genenta's CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl globenewswire.com - 4 months ago
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA). globenewswire.com - 5 months ago
7 Penny Biotech Stocks to Triple Your Investment One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. investorplace.com - 9 months ago
Genenta Welcomes New Directors John L. Cantello, Lauren H. MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman. globenewswire.com - 9 months ago
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial globenewswire.com - 1 year ago
Genenta to Present at Upcoming Scientific and Investor Conferences MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences. globenewswire.com - 1 year ago
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication globenewswire.com - 1 year ago
Genenta to Present at Upcoming Scientific and Investor Conferences MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming scientific and investor conferences. globenewswire.com - 2 years ago
Genenta to Present at Upcoming Investor Conferences MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming investor conferences in September and October. globenewswire.com - 2 years ago
8. Profile Summary

Genenta Science S.p.A. GNTA

image
COUNTRY IT
INDUSTRY Biotechnology
MARKET CAP $ 69.7 M
Dividend Yield 0.00%
Description Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Contact Via Olgettina No. 58, Milan, MI, 20132 https://www.genenta.com
IPO Date Dec. 15, 2021
Employees 14
Officers Dr. Stefania Mazzoleni Ph.D. Director of Program Development Mr. Pierluigi Paracchi Co-Founder, Chairman & Chief Executive Officer Ms. Barbara Regonini Director of Finance Mr. Richard B. Slansky Chief Financial Officer Dr. Bernard Rudolph Gentner M.D., Ph.D. Co-Founder & Member of the Executive Scientific Board Dr. Luigi Naldini M.D., Ph.D. Co-Founder & Chairman of the Executive Scientific Board Dr. Carlo Russo M.D. Chief Medical Officer & Head of Development